MedTrace Logo

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

NCT04701918 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-01-22

No results posted yet for this study

Summary

This research study is examining the effectiveness of pembrolizumab plus cryoablation or aveluma plus cryoablation on people with urothelial carcinoma, including bladder cancer, that has spread.

Conditions

Interventions

DRUG

Pembrolizumab

Intravenous injection through a vein (IV) every 3 weeks

PROCEDURE

Cryoablation

Needle inserted through the skin and into the tumor using CT guidance

DRUG

Avelumab

Intravenous injection through a vein (IV) every 2 weeks

Sponsors & Collaborators

  • Biocompatibles UK Ltd

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Eric Wehrenberg-Klee, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-04
Primary Completion
2025-12-01
Completion
2025-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04701918 on ClinicalTrials.gov